切换至 "中华医学电子期刊资源库"

中华介入放射学电子杂志 ›› 2025, Vol. 13 ›› Issue (02) : 164 -169. doi: 10.3877/cma.j.issn.2095-5782.2025.02.010

综述

动脉栓塞术用于良性前列腺增生治疗的现状讨论与展望
谢强1, 解银立2, 王黎洲1,()   
  1. 1. 550004 贵州贵阳,贵州医科大学附属医院介入科
    2. 553001 贵州六盘水,六盘水市人民医院介入科
  • 收稿日期:2024-07-11 出版日期:2025-05-25
  • 通信作者: 王黎洲
  • 基金资助:
    六盘水市科技计划(52020-2023-0-1-48)

Discussion and prospects on the current status of arterial embolization in the treatment of benign prostatic hyperplasia

Qiang Xie1, Yinli Xie2, Lizhou Wang1,()   

  1. 1. Department of Interventional Radiology,Affiliated Hospital of Guizhou Medical University,Guizhou Guiyang 550004
    2. Department of Interventional Radiology,The Peoples Hospital of Dipanshi city,Guizhou Liupanshui 553001,China
  • Received:2024-07-11 Published:2025-05-25
  • Corresponding author: Lizhou Wang
引用本文:

谢强, 解银立, 王黎洲. 动脉栓塞术用于良性前列腺增生治疗的现状讨论与展望[J/OL]. 中华介入放射学电子杂志, 2025, 13(02): 164-169.

Qiang Xie, Yinli Xie, Lizhou Wang. Discussion and prospects on the current status of arterial embolization in the treatment of benign prostatic hyperplasia[J/OL]. Chinese Journal of Interventional Radiology(Electronic Edition), 2025, 13(02): 164-169.

前列腺动脉栓塞术(prostatic arterial embolization, PAE)目前在治疗良性前列腺增生(benign prostatic hyperplasia, BPH)引起的下尿路症状的安全性和有效性相比传统经尿道前列腺切除术颇具优势。然而,由于该治疗方案依然面临多种操作难点有待讨论和解决,PAE 方案选择治疗优先级仍较低。众多学者为求解决PAE 难点问题以提高临床获益进行了大量研究。文章通过广泛查阅PAE 用以BPH 相关文献报道,针对PAE 在术中、术后以及远期随访所面临的焦点、难点问题做综述讨论并总结。

Prostatic artery embolization (PAE) has the advantage of safety and efficacy compared to the transurethral resection of the prostate (TURP) in the treatment of lower urinary tract symptoms (LUTS)caused by benign prostatic hyperplasia (BPH).However, due to various operational challenges and difficulties that remain to be discussed and resolved with this treatment approach, PAE does not hold a high priority in treatment options.Numerous scholars have conducted extensive research to solve these problems of PAE and improve clinical benefits.By extensively reviewing relevant literature reports on PAE for BPH, this paper comprehensively discusses and summarizes the difficulties encountered during PAE procedures, post-surgery,and in long-term follow-ups.

[1]
Launer BM, McVary KT, Ricke WA, et al.The rising worldwide impact of benign prostatic hyperplasia[J].BJU Int, 2021,127(6):722-728.
[2]
Zi H, Liu MY, Luo LS, et al.Global burden of benign prostatic hyperplasia, urinary tract infections, urolithiasis, bladder cancer,kidney cancer, and prostate cancer from 1990 to 2021[J].Mil Med Res.2024,11(1):64.
[3]
Ganesan V, Agarwal D.Medical advancements in benign prostatic hyperplasia treatments[J].Curr Urol Rep,2024,25(5):93-98.
[4]
Koudonas A, Anastasiadis A, Tsiakaras S, et al.Overview of current pharmacotherapeutic options in benign prostatic hyperplasia[J].Expert Opin Pharmacother, 2023,24(14):1609-1622.
[5]
Sapoval M, Thiounn N, Descazeaud A, et al.Prostatic artery embolisation versus medical treatment in patients with benign prostatic hyperplasia (PARTEM): a randomised, multicentre,open-label, phase 3, superiority trial[J].Lancet Reg Health Eur,2023,31:100672.
[6]
Teng TC, Shao IH, Hsu YC, et al.Risk factors of emergency room visits for bleeding complications following transurethral procedures in the treatment of benign prostatic hyperplasia: a retrospective cohort study[J].Clin Interv Aging, 2021,16:1747-1756.
[7]
Wang RL, Lin FF, Ruan DD, et al.A correlation study between prostate necrosis rate calculated by 3D Slicer software and clinical efficacy of prostatic artery embolization, along with an analysis of predictors of clinical success after prostatic artery embolization[J].Abdom Radiol (NY), 2024, 49(3):927-938.
[8]
Jankauskas T, Burzinskis E, Kaupas RS, et al.Prostatic artery embolization as a treatment option for symptomatic benign prostatic hyperplasia: results from the prospective follow-up study in Lithuania[J].Medicina (Kaunas), 2023,59(10).
[9]
DeMeritt JS, Elmasri FF, Esposito MP, et al.Relief of benign prostatic hyperplasia-related bladder outlet obstruction after transarterial polyvinyl alcohol prostate embolization[J].J Vasc Interv Radiol, 2000,11(6):767-770.
[10]
Insausti I, Saez de Ocariz A, Galbete A, et al.Randomized comparison of prostatic artery embolization versus transurethral resection of the prostate for treatment of benign prostatic hyperplasia[J].J Vasc Interv Radiol, 2020,31(6):882-890.
[11]
Radwan A, Farouk A, Higazy A, et al.Prostatic artery embolization versus transurethral resection of the prostate in management of benign prostatic hyperplasia[J].Prostate Int,2020,8(3):130-133.
[12]
楼文杰, 何帅, 斯艳阳, 等.前列腺动脉栓塞治疗良性前列腺增生的近期疗效和安全性分析[J].医学影像学杂志,2023,33(7):1231-1235.
[13]
Mullhaupt G, Hechelhammer L, Engeler DS, et al.In-hospital cost analysis of prostatic artery embolization compared with transurethral resection of the prostate: post hoc analysis of a randomized controlled trial[J].BJU Int, 2019,123(6):1055-1060.
[14]
Bhatia S, Sinha VK, Harward S, et al.Prostate artery embolization in patients with prostate volumes of 80 ml or more: a singleinstitution retrospective experience of 93 patients[J].J Vasc Interv Radiol, 2018,29(10):1392-1398.
[15]
Bilhim T, Pisco JM, Rio Tinto H, et al.Prostatic arterial supply:anatomic and imaging findings relevant for selective arterial embolization[J].J Vasc Interv Radiol, 2012,23(11):1403-1415.
[16]
DeMeritt JS, Wajswol E, Wattamwar A, et al.Duplicated prostate artery central gland blood supply: a retrospective analysis and classification system[J].J Vasc Interv Radiol, 2018,29(11):1595-1600.e9.
[17]
Svarc P, Hagen T, Waltenburg H, et al.Center experience and other determinants of patient radiation exposure during prostatic artery embolization: a retrospective study in three Scandinavian centers[J].Eur Radiol, 2022,32(4):2404-2413.
[18]
王福安, 黄文诺, 吕朋华, 等.C臂锥体束CT技术在前列腺动脉栓塞术中的应用价值[J].中华介入放射学电子杂志, 2017,5(2):79-82.
[19]
Diaz TA, Benson B, Clinkenbeard A, et al.MRI evaluation of patients before and after interventions for benign prostatic hyperplasia: an update[J].AJR Am J Roentgenol, 2022,218(1):88-99.
[20]
Alizadeh LS, Gyano M, Gog I, et al.Initial experience using digital variance angiography in context of prostatic artery embolization in comparison with digital subtraction angiography[J].Acad Radiol, 2023,30(4):689-697.
[21]
刘凯, 李晋, 蒋贝, 等.3D旋转DSA在前列腺动脉栓塞术中的应用价值分析[J].中华介入放射学电子杂志, 2021,9(3):288-293.
[22]
Bilhim T, Costa NV, Torres D, et al.Long-term outcome of prostatic artery embolization for patients with benign prostatic hyperplasia: single-centre retrospective study in 1072 patients over a 10-year period[J].Cardiovasc Intervent Radiol, 2022,45(9):1324-1336.
[23]
Hwang JH, Park SW, Chang IS, et al.Comparison of nonspherical polyvinyl alcohol particles and microspheres for prostatic arterial embolization in patients with benign prostatic hyperplasia[J].Biomed Res Int, 2017,2017:8732351.
[24]
Raizenne BL, Zheng X, Oumedjbeur K, et al.Prostatic artery embolization compared to transurethral resection of the prostate and prostatic urethral lift: a real-world population-based study[J].World J Urol, 2023,41(1):179-188.
[25]
Goncalves OM, Carnevale FC, Moreira AM, et al.Comparative study using 100-300 versus 300-500 mum microspheres for symptomatic patients due to enlarged-bph prostates[J].Cardiovasc Intervent Radiol, 2016,39(10):1372-1378.
[26]
吴少杰, 蔡森林, 唐仪, 等.前列腺动脉栓塞术治疗前列腺源性血尿临床效果[J].介入放射学杂志, 2022,31(2):176-179.
[27]
Pilan BF, de Assis AM, Moreira AM, et al.Protection of nontarget structures in prostatic artery embolization[J].Radiol Bras, 2022,55(1):6-12.
[28]
Ayyagari R, Powell T, Staib L, et al.Case-control comparison of conventional end-hole versus balloon-occlusion microcatheter prostatic artery embolization for treatment of symptomatic benign prostatic hyperplasia[J].J Vasc Interv Radiol,2019,30(9):1459-1470.
[29]
Zumstein V, Binder J, Gusewell S, et al.Radiation exposure during prostatic artery embolisation: a systematic review and calculation of associated risks[J].Eur Urol Focus, 2021,7(3):608-611.
[30]
Laborda A, De Assis AM, Ioakeim I, et al.Radiodermitis after prostatic artery embolization: case report and review of the literature[J].Cardiovasc Intervent Radiol, 2015,38(3):755-759.
[31]
McDonald JS, Larson NB, Schmitz JJ, et al.Acute adverse events after iodinated contrast agent administration of 359,977 injections: a single-center retrospective study[J].Mayo Clin Proc, 2023,98(12):1820-1830.
[32]
Moschouris H, Stamatiou K, Spanomanolis N, et al.A retrospective, single-center study of technical-procedural factors affecting radiation dose during prostatic artery embolization[J].Cureus, 2022,14(8):e27728.
[33]
Feng S, Tian Y, Liu W, et al.Prostatic arterial embolization treating moderate-to-severe lower urinary tract symptoms related to benign prostate hyperplasia: a meta-analysis[J].Cardiovasc Intervent Radiol, 2017,40(1):22-32.
[34]
Ray AF, Powell J, Speakman MJ, et al.Efficacy and safety of prostate artery embolization for benign prostatic hyperplasia: an observational study and propensity-matched comparison with transurethral resection of the prostate (the UK-ROPE study)[J].BJU Int, 2018,122(2):270-282.
[35]
Bagla S, Smirniotopoulos JB, Orlando JC, et al.Comparative analysis of prostate volume as a predictor of outcome in prostate artery embolization[J].J Vasc Interv Radiol, 2015,26(12):1832-1838.
[36]
Wang XY, Chai YM, Huang WH, et al.Prostate artery embolization on lower urinary tract symptoms related to benign prostatic hyperplasia: a systematic review and meta-analysis[J].World J Clin Cases, 2022,10(32):11812-11826.
[37]
Feng Y, Wu J, Zhu H, et al.Three-dimensional measurement and analysis of benign prostatic hyperplasia[J].Transl Androl Urol,2021,10(6):2384-2396.
[38]
Yu SCH, Cho CCM, Hung EHY, et al.Thickness-to-height ratio of intravesical prostatic protrusion predicts the clinical outcome and morbidity of prostatic artery embolization for benign prostatic hyperplasia[J].J Vasc Interv Radiol, 2019,30(11):1807-1816.
[39]
Sun F, Lucas-Cava V, Sanchez-Margallo FM.Clinical predictive factors in prostatic artery embolization for symptomatic benign prostatic hyperplasia: a comprehensive review[J].Transl Androl Urol, 2020,9(4):1754-1768.
[40]
Wang RL, Lin FF, Ruan DD, et al.A correlation study between prostate necrosis rate calculated by 3D Slicer software and clinical efficacy of prostatic artery embolization, along with an analysis of predictors of clinical success after prostatic artery embolization[J].Abdom Radiol (NY), 2024,49(3):927-938.
[1] 杨娟, 杜雪, 田旺, 吕文杰, 杨媛媛, 尹宗智. 子宫动脉栓塞术对阴道分娩后胎盘滞留及合并胎盘植入患者清宫术治疗胎盘滞留的疗效分析[J/OL]. 中华妇幼临床医学杂志(电子版), 2025, 21(01): 114-121.
[2] 潘兴赫, 董翔, 杨海洋, 张雪斌, 甘卫东. 超选择性前列腺动脉栓塞治疗伴急性尿潴留的高危高龄前列腺增生[J/OL]. 中华腔镜泌尿外科杂志(电子版), 2024, 18(03): 237-242.
[3] 王重阳, 滑文文, 魏丽, 邱应和, 杨发才, 李函娟. 免疫治疗联合局部区域疗法治疗中晚期肝癌的研究进展[J/OL]. 中华肝脏外科手术学电子杂志, 2025, 14(02): 302-307.
[4] 宋然, 郑雅各. 仑伐替尼联合肝动脉插管化疗栓塞术治疗不可切除晚期肝癌的疗效及生存率影响因素分析[J/OL]. 中华消化病与影像杂志(电子版), 2025, 15(02): 120-124.
[5] 鲍乐, 刘颖, 王友彬, 陈龙, 朱玉芝, 梁爽, 权鹤太, 李鹏飞. 还阳通络灸在原发性肝癌介入治疗中的临床应用研究[J/OL]. 中华消化病与影像杂志(电子版), 2024, 14(03): 197-202.
[6] 蔡晓雯, 李慧景, 丘婕, 杨翼帆, 吴素贤, 林玉彤, 何秋娜. 肝癌患者肝动脉化疗栓塞术后疼痛风险预测模型的构建及验证[J/OL]. 中华临床医师杂志(电子版), 2024, 18(08): 722-728.
[7] 陈文, 张兴华, 严海涛, 张金星, 刘圣, 施海彬, 祖庆泉. 经动脉化疗栓塞术联合仑伐替尼和免疫检查点抑制剂对不可切除肝细胞癌的安全性及有效性[J/OL]. 中华介入放射学电子杂志, 2025, 13(02): 117-122.
[8] 姜国松, 王佳, 谢万木, 李云, 李金萍, 黄强. 支气管动脉栓塞术后并发症及其预防和处理[J/OL]. 中华介入放射学电子杂志, 2025, 13(01): 1-6.
[9] 赵雅静, 严海涛, 张金星, 茅矛, 刘圣, 施海彬, 祖庆泉. 呼吸康复在支气管扩张伴咯血患者经动脉栓塞术后的疗效研究[J/OL]. 中华介入放射学电子杂志, 2025, 13(01): 14-17.
[10] 马惠军, 赵晓慧, 徐蕾, 何子寅, 杨楠, 李艾, 牛洪涛, 杜彪. 低剂量支气管动脉CT 血管造影在支气管动脉栓塞术前的可行性研究[J/OL]. 中华介入放射学电子杂志, 2025, 13(01): 23-28.
[11] 王卫明, 张艺菲, 陈炜, 秦浩, 杨宇光, 王俊, 王琴, 夏莹, 施博文, 董宇超, 白冲, 黄海东. 左主支气管动脉肺静脉瘘致气道狭窄及反复咯血一例[J/OL]. 中华介入放射学电子杂志, 2024, 12(04): 323-326.
[12] 崔伟, 叶苏意, 邓屹, 陈晓明, 张靖, 李静, 许荣德. 载药微球支气管动脉化疗栓塞术治疗难治性非小细胞肺癌的临床疗效及安全性[J/OL]. 中华介入放射学电子杂志, 2024, 12(04): 311-316.
[13] 崔伟, 邓屹, 叶苏意, 李静, 陈晓明, 张靖, 许荣德. 载药微球支气管动脉化疗栓塞术治疗罕见非小细胞肺癌的临床疗效和安全性分析[J/OL]. 中华介入放射学电子杂志, 2024, 12(04): 303-310.
[14] 崔伟, 李静, 陈晓明, 张靖, 邓屹, 许荣德. 载药微球支气管动脉化疗栓塞术治疗非小细胞肺癌的研究进展[J/OL]. 中华介入放射学电子杂志, 2024, 12(04): 289-295.
[15] 赖海洋, 吴可通, 刘洋, 李丹, 彭焘, 万源, 张波. 术前经动脉栓塞在椎体转移瘤切除术中的应用[J/OL]. 中华介入放射学电子杂志, 2024, 12(04): 327-332.
阅读次数
全文


摘要


AI


AI小编
你好!我是《中华医学电子期刊资源库》AI小编,有什么可以帮您的吗?